<DOC>
	<DOCNO>NCT00799643</DOCNO>
	<brief_summary>Growing evidence recent year support potential role low grade chronic inflammation pathogenesis insulin resistance type 2 diabetes . In study determine whether salsalate , member commonly use Non-Steroidal Anti-Inflammatory Drug ( NSAID ) class , effective lowering sugar patient type 2 diabetes . The study determine whether salicylate represent new pharmacological option diabetes management . The study conduct two stage . Enrollment first stage complete . The primary objective first stage select dose salsalate well-tolerated demonstrates trend toward improvement glycemic control . The primary objective Stage 2 study evaluate effect salsalate blood sugar control diabetes ; tolerability salsalate use patient type 2 diabetes ( T2D ) ; effect salsalate measure inflammation , metabolic syndrome , cardiac risk .</brief_summary>
	<brief_title>Targeting Inflammation Using Salsalate Type 2 Diabetes-stage II</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Salicylsalicylic acid</mesh_term>
	<mesh_term>Sodium Salicylate</mesh_term>
	<criteria>1 . Type 2 diabetes diet exercise therapy monotherapy metformin , insulin secretagogue ( include SFU , nonSFU , dipeptidyl peptidase IV ( DPP4 ) inhibitor ) , alphaglucosidase inhibitor , bile acid sequestrants ( dosed per day study drug administer ≥ 4 hour prior sequestrant ) ; combination two maximal dose . Dosing must stable 8 week prior screen . Participant must diagnose T2D least 8 week screen . 2 . FPG ≤ 225 mg/dL HbA1c≥7 % ≤ 9.5 % screening . 3 . Age ≥18 &lt; 75 4 . Women childbearing potential agree use appropriate contraceptive method ( hormonal , IUD , diaphragm ) 1 . No prior participation Stage I TINSALT2D ; exception : participant fail screen HbA1c Stage I allow rescreen Stage II . 2 . Type 1 diabetes and/or history ketoacidosis determine medical history 3 . History severe diabetic neuropathy include autonomic neuropathy , gastroporesis lower limb ulceration amputation 4 . History longterm therapy insulin ( &gt; 30 day ) within last year 5 . Therapy rosiglitazone ( Avandia ) pioglitazone ( Actos ) , alone combination previous 6 month ; extendin4 ( Byetta ) , alone combination previous 3 month 6 . Pregnancy lactation 7 . Patients require oral corticosteroid within 3 month recurrent continuous oral corticosteroid treatment ( 2 week ) 8 . Use weight loss drug [ e.g. , Xenical ( orlistat ) , Meridia ( sibutramine ) , Acutrim ( phenylpropanolamine ) , similar overthecounter medication ] within 3 month screen intentional weight loss ≥ 10 lb previous 6 month 9 . Surgery within 30 day prior screen 10 . Serum creatinine &gt; 1.4 woman &gt; 1.5 men eGFR &lt; 60 [ possible chronic kidney disease stage 3 great calculate use Modification Diet Renal Disease ( MDRD ) equation 11 . History chronic liver disease include hepatitis B C 12 . History peptic ulcer endoscopy demonstrate gastritis 13 . History acquire immune deficiency syndrome human immunodeficiency virus ( HIV ) 14 . History malignancy , except participant diseasefree great 10 year , whose malignancy basal squamous cell skin carcinoma 15 . New York Heart Association Class III IV cardiac status hospitalization congestive heart failure 16 . History unstable angina , myocardial infarction , cerebrovascular accident , transient ischemic attack revascularization within 6 month 17 . Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 95 mmHg three assessment one day ) . If blood pressure medication , dose stable 2 week prior randomization . 18 . History drug alcohol abuse , current weekly alcohol consumption &gt; 10 units/week ( 1 unit = 1 beer , 1 glass wine , 1 mixed DCCktail contain 1 ounce alcohol ) 19 . Hemoglobin &lt; 12 g/dL ( male ) , &lt; 10 g/dL ( female ) screening* 20 . Platelets &lt; 100,000 cu mm screen 21 . AST ( SGOT ) &gt; 2.50 x ULN ALT ( SGPT ) &gt; 2.50 x ULN screen 22 . Total Bilirubin &gt; 1.50 x ULN screen 23 . Triglycerides ( TG ) &gt; 500 mg/dL screen 24 . Poor mental function reason expect patient difficulty comply requirement study 25 . Previous allergy aspirin 26 . Chronic continuous use ( daily 7 day ) nonsteroidal antiinflammatory drug within precede 2 month 27 . Use warfarin ( Coumadin ) , clopidogrel ( Plavix ) , dipyridamole ( Persantine ) , heparin anticoagulant 28 . Use probenecid ( Benemid , Probalan ) , sulfinpyrazone ( Anturane ) uricosuric agent 29 . Macroalbuminuria , define spot urine protein &gt; 300 mcg/mg Cr screen 30 . Preexisting chronic tinnitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus ( T2D )</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Obesity</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Salicylates</keyword>
</DOC>